Leronlimab was studied in combination with Keytrud
Post# of 155122
(Total Views: 417)
Posted On: 07/09/2025 3:27:25 PM
Leronlimab was studied in combination with Keytruda (pembrolizumab), a known cancer immunotherapy, for the treatment of certain cancers, including metastatic triple-negative breast cancer (mTNBC). Leronlimab is a CCR5 antagonist, while Keytruda is a PD-1 inhibitor. The combination aims to enhance the anti-tumor effect by potentially reversing T-cell exhaustion and inducing an inflamed tumor microenvironment that is more susceptible to immunotherapy.
Merck should just do combo therapy.
Merck should just do combo therapy.
(3)
(0)